Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study

Roy Vergis; Catherine M Corbishley; Andrew R Norman; Jaclyn Bartlett; Sameer Jhavar; Michael Borre; Sara Heeboll; Alan Horwich; Robert Huddart; Vincent Khoo; Ros Eeles; Colin Cooper; Matthew Sydes; David Dearnaley; Chris Parker

doi:10.1016/S1470-2045(08)70076-7

Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study

Roy Vergis, Catherine M Corbishley, Andrew R Norman, Jaclyn Bartlett, Sameer Jhavar, Michael Borre, Sara Heeboll, Alan Horwich, Robert Huddart, Vincent Khoo, Ros Eeles, Colin Cooper, Matthew Sydes, David Dearnaley, Chris Parker

Research output: Contribution to journal › Article › peer-review

255 Citations (SciVal)

Abstract

Expression of intrinsic markers of tumour hypoxia and angiogenesis are important predictors of radiotherapeutic, and possibly surgical, outcome in several cancers. Extent of tumour hypoxia in localised prostate cancer is comparable to that in other cancers, but few data exist on the association of extent of tumour hypoxia with treatment outcome. We aimed to study the predictive value of intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer, both in patients treated with radiotherapy and in those treated surgically.

Original language	English
Pages (from-to)	342-351
Number of pages	10
Journal	The Lancet Oncology
Volume	9
Issue number	4
DOIs	https://doi.org/10.1016/S1470-2045(08)70076-7
Publication status	Published - Apr 2008

Keywords

Aged
Aged 80 and over
Biopsy (Needle)
Cell Hypoxia
Cohort Studies
Humans
Hypoxia-Inducible Factor 1
Immunohistochemistry
Male
Middle Aged
Neoplasm Staging
Neovascularization (Pathologic)
Osteopontin
Probability
Prognosis
Proportional Hazards Models
Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms
Radiotherapy, Conformal
Randomized Controlled Trials as Topic
Reference Values
Retrospective Studies
Risk Assessment
Survival Analysis
Treatment Outcome
Tumor Markers (Biological)
Vascular Endothelial Growth Factor A

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(08)70076-7

Cite this

Vergis, R., Corbishley, C. M., Norman, A. R., Bartlett, J., Jhavar, S., Borre, M., Heeboll, S., Horwich, A., Huddart, R., Khoo, V., Eeles, R., Cooper, C., Sydes, M., Dearnaley, D., & Parker, C. (2008). Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. The Lancet Oncology, 9(4), 342-351. https://doi.org/10.1016/S1470-2045(08)70076-7

@article{8bcdbde07d47450e8ab7ad1d6bfbde9f,

title = "Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study",

abstract = "Expression of intrinsic markers of tumour hypoxia and angiogenesis are important predictors of radiotherapeutic, and possibly surgical, outcome in several cancers. Extent of tumour hypoxia in localised prostate cancer is comparable to that in other cancers, but few data exist on the association of extent of tumour hypoxia with treatment outcome. We aimed to study the predictive value of intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer, both in patients treated with radiotherapy and in those treated surgically.",

keywords = "Aged, Aged 80 and over, Biopsy (Needle), Cell Hypoxia, Cohort Studies, Humans, Hypoxia-Inducible Factor 1, Immunohistochemistry, Male, Middle Aged, Neoplasm Staging, Neovascularization (Pathologic), Osteopontin, Probability, Prognosis, Proportional Hazards Models, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Radiotherapy, Conformal, Randomized Controlled Trials as Topic, Reference Values, Retrospective Studies, Risk Assessment, Survival Analysis, Treatment Outcome, Tumor Markers (Biological), Vascular Endothelial Growth Factor A",

author = "Roy Vergis and Corbishley, {Catherine M} and Norman, {Andrew R} and Jaclyn Bartlett and Sameer Jhavar and Michael Borre and Sara Heeboll and Alan Horwich and Robert Huddart and Vincent Khoo and Ros Eeles and Colin Cooper and Matthew Sydes and David Dearnaley and Chris Parker",

year = "2008",

month = apr,

doi = "10.1016/S1470-2045(08)70076-7",

language = "English",

volume = "9",

pages = "342--351",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier",

number = "4",

}

Vergis, R, Corbishley, CM, Norman, AR, Bartlett, J, Jhavar, S, Borre, M, Heeboll, S, Horwich, A, Huddart, R, Khoo, V, Eeles, R, Cooper, C, Sydes, M, Dearnaley, D & Parker, C 2008, 'Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study', The Lancet Oncology, vol. 9, no. 4, pp. 342-351. https://doi.org/10.1016/S1470-2045(08)70076-7

Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment : a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. / Vergis, Roy; Corbishley, Catherine M; Norman, Andrew R et al.

In: The Lancet Oncology, Vol. 9, No. 4, 04.2008, p. 342-351.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment

T2 - a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study

AU - Vergis, Roy

AU - Corbishley, Catherine M

AU - Norman, Andrew R

AU - Bartlett, Jaclyn

AU - Jhavar, Sameer

AU - Borre, Michael

AU - Heeboll, Sara

AU - Horwich, Alan

AU - Huddart, Robert

AU - Khoo, Vincent

AU - Eeles, Ros

AU - Cooper, Colin

AU - Sydes, Matthew

AU - Dearnaley, David

AU - Parker, Chris

PY - 2008/4

Y1 - 2008/4

N2 - Expression of intrinsic markers of tumour hypoxia and angiogenesis are important predictors of radiotherapeutic, and possibly surgical, outcome in several cancers. Extent of tumour hypoxia in localised prostate cancer is comparable to that in other cancers, but few data exist on the association of extent of tumour hypoxia with treatment outcome. We aimed to study the predictive value of intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer, both in patients treated with radiotherapy and in those treated surgically.

AB - Expression of intrinsic markers of tumour hypoxia and angiogenesis are important predictors of radiotherapeutic, and possibly surgical, outcome in several cancers. Extent of tumour hypoxia in localised prostate cancer is comparable to that in other cancers, but few data exist on the association of extent of tumour hypoxia with treatment outcome. We aimed to study the predictive value of intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer, both in patients treated with radiotherapy and in those treated surgically.

KW - Aged

KW - Aged 80 and over

KW - Biopsy (Needle)

KW - Cell Hypoxia

KW - Cohort Studies

KW - Humans

KW - Hypoxia-Inducible Factor 1

KW - Immunohistochemistry

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Neovascularization (Pathologic)

KW - Osteopontin

KW - Probability

KW - Prognosis

KW - Proportional Hazards Models

KW - Prostate-Specific Antigen

KW - Prostatectomy

KW - Prostatic Neoplasms

KW - Radiotherapy, Conformal

KW - Randomized Controlled Trials as Topic

KW - Reference Values

KW - Retrospective Studies

KW - Risk Assessment

KW - Survival Analysis

KW - Treatment Outcome

KW - Tumor Markers (Biological)

KW - Vascular Endothelial Growth Factor A

U2 - 10.1016/S1470-2045(08)70076-7

DO - 10.1016/S1470-2045(08)70076-7

M3 - Article

C2 - 18343725

VL - 9

SP - 342

EP - 351

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 4

ER -